Adil Dinata Simangunsong, Aryati Aryati, Azimatul Karimah, Ferdy Royland Marpaung


Introduction. Vitamin D deficiency is a common health problem that occurs in various countries. Vitamin D deficiency is linked to various diseases such as kidney failure, liver damage, atherosclerosis, obesity and psychiatric disorders such as depression and schizophrenia. This study aimed to analyze the correlation between serum vitamin D levels and schizophrenia severity.


Methods. Schizophrenia patients who visited the Inpatient and Outpatient Clinic Department of Psychiatry of the Dr. Soetomo Hospital Surabaya. This was a cross-sectional observational study, conducted in December 2017 - April 2018 . The subjects consisted of 53 schizophrenia patients, vitamin D levels < 30 ng /mL (35 (66.04%); > 30 ng/mL (18 (33.96%). Serum vitamin D levels test by enzyme linked fluorescent assay (ELFA) method using Vidas. The severity of schizophrenia was measured using a positive and negative syndrome scale (PANSS) score.


Results. Mean serum vitamin D levels in schizophrenia were 23.45 ± 9.16 ng / mL, serum vitamin D levels in males were 24.36 ± 9.80 ng / ml and females 21.96 ± 7.98 ng / ml. The mean serum vitamin D level and PANSS scores of positive symptoms was 16.42 ± 8.50. The mean serum vitamin D level and PANSS scores of negative symptoms was 15.60 ± 6.12. The mean serum vitamin D level and PANSS scores of general psychopathology symptoms was 29.51 ± 10.29. The statistical results showed no association between vitamin D levels and PANSS scores.


Conclusion. The results of this study indicated low serum vitamin D levels in schizophrenia. There was no association between serum vitamin D levels and the severity of schizophrenia using PANSS scores.


Vitamin D, vitamin D deficiency, schizophrenia, PANSS score


Amaral AD, Calhau C and Coelho, 2014. Schizophrenia: Implication of vitamin D deficit on brain development. Int J Clin Neurosc Ment Health, 1: 16-25.

Graham KA, Keefe RS and Lieberman JA, et al, 2015. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. J Intervent Psychiatry, 9: 397–405.

Valipour G, Saneei P and Esmaillzadeh A, 2014. Serum vitamin D levels in relation to schizophrenia: A systematic review and meta-analysis of observational studies. J Clin Endocrinol Metab, 99: 3863–72.

Patel R K, Cherian J, Gohil K, Atkinson D, 2014. Schizophrenia: Overview and Treatment Options. P&T Community. Vol 39 (9). Pg.638-45.

Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, et al. (1992). Schizophrenia: Manifestations, incidence and course in different cultures: A World Health Organization ten-country study. Cambridge University Press. Pg, 6-7.

Berbato A, 1998. Schizophrenia and public health. Division of Mental Health and

Prevention of Substance Abuse. World Health Organization. Chapter 3, 6-7

Meli G, Ottl B, Paladini A and Cataldi L. 2012. Prenatal and perinatal risk factors of schizophrenia. J Matern Fetal Neonatal Med, 25: 2559-63.

Narr KL, Toga AW and Szeszko P. 2005. Cortical thinnin in cingulated and occipital cortices in first episode schizophrenia. Biol Psychiatry, 58: 32-40.

McGrath JJ, Burne TH, Feron F, Mackay-Sim A dan Eyles DW, 2011. Developmental Vitamin D deficiency and risk of schizophrenia: A ten-year update. Schizophr Bull, 36: 1073-8.

Berg AO, Melle I, Torjesen PA, Lien L, Hauff E dan Andreassen OA, 2010. A cross-sectional study of vitamin D deficiency among immigrants and Norwegians with psychosis compared to the general population. J Clin Psychiatry, 71: 1598-604.

Bulut SD, Bulut S, Atalan DG, Berkol T, Gurcay E, Turker T, et al, 2016. The Relationship between Symptom Severity and Low Vitamin D Levels in Patients with Schizophrenia. Plos one 11(10): 1-13

Itzhaky D, Amital D and Gorden K, 2012. Low serum Vitamin D concentrations in patients with schizophrenia. IMAJ, 14: 88–92.

Yüksel RN, Altunsoy N, Tikir B, Kuluk MC, Unal K, et al, 2014. Correlation Between Total Vitamin D Levels and Psychotic Psychopathology in Patients With Schizophrenia : Therapeutic Implications for Add-on Vitamin D Augmentation. Ther Adv Psychopharmacol; Vol. 4(6) 268-275.

Arroll MA, Wilder L, Neil J, 2014. Nutritional interventions for the adjunctive treatment of schizophrenia: a brief review. Nutrition Journal, 13:1-9

Sadock BJ, Sadock VA. In: Kaplan & Sadock’s synopsis of psychiatry behavioral sciences/ clinical psychiatry. 11th ed. Philadelphia: Lippincott Williams & Wilkins; 2015. p. 649-701.

Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B, 2015. A Role for Estrogen in Schizophrenia: Clinical and Preclinical Findings. International Journal of Endocrinology. 1-17

Kesby JP, Cui Xiaoying, Burne THJ, Eyles DW, Altered Dopamine Ontogeny in The Developmentally Vitamin D Deficient Rat and Its Relevance to Schizophrenia. Fontiers in Cellular Neuroscience. 2013; Vol. 7. Article 111: p. 1-12.

Sotodeh-Asl N, Tamadon M R, Malek F and Zahmatkesh M, 2014. Vitamin D deficiency and psychological disorders. J Parathyroid Dis, 2: 21–5.

Cieslak K, Feingoid J, Antonius D, Messinger JW, Dracxler R, et al. Low Vitamin D Levels Predict Clinical Features of Schizophrenia. National Institute of Health Public Acces.`2015; 1 : p. 1-7.

Lally J, Gardner-Sood P and Firdosi M, 2016. Clinical correlates of vitamin D deficiency in established psychosis. BMC Psychiatry, 16: 1-9.

Pearce S.H, Cheetham T.D. Diagnosis and Management of Vitamin D Deficiency. BMJ 2010;340.

Crews M, Lally J, Gardner- Sood P, Howes O, Bonaccorso S, et al. Vitamin D deficiency in first episode psychosis: a case-control study. Schizophr Res. 2013; 150(2-3): 533-537.

Hadded C, Zoghbi M and Hallits S, et al, 2017. Vitamin D levels in lebanese patients with schizophrenia: A Case-Control Study. Ann Nutri Dis Ther, 17: 1041-6.

Wrzosek M, Lukaszkiewicz J and Wrzosek M, 2013. Vitamin D and the central nervous system. Pharmacological reports, 65: 271-8.

Albayrak Y, Unsal C, Beyazyuz M, Unal A, Kuloglu M. 2013. Reduced total antioxidant level and increased oxidative stress in patients with deficit schizophrenia: a preliminary study. Prog. Neuropsychopharmacol. Bol. Psychiatry 45, 144–149.

Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014; 14: 97-102.



  • There are currently no refbacks.